{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-004753","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.773801+00:00","generated_at":"2026-06-18T20:51:02.601907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia Pharma Q4 NUPLAZID sales $136.5M, full-year $517.2M; PDUFA for trofinetide March 12","bullets":["Net sales $517.2M in 2022, up 7% YoY; Q4 sales $136.5M, up 4% YoY.","Net loss $216.0M for 2022 vs $167.9M in 2021; Q4 loss $41.7M ($0.26/share).","PDUFA action date March 12, 2023 for trofinetide for Rett syndrome.","2023 guidance: NUPLAZID sales $520-550M; R&D $235-255M; SG&A $360-380M.","Doug Williamson appointed EVP Head of R&D in Jan 2023; Serge Stankovic retired."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-004753","json":"https://secwatch.observer/filing/0000950170-23-004753.json","markdown":"https://secwatch.observer/filing/0000950170-23-004753.md","text":"https://secwatch.observer/filing/0000950170-23-004753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/acad-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T20:51:02.601907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02df10567475ad06d35a19cd8307344726bc497b","claim":"ACADIA PHARMACEUTICALS INC reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"498f730869990ff6733bcb805d1938d7feb28660","claim":"ACADIA PHARMACEUTICALS INC reported financial results for the full year ended December 31, 2022.","evidence_excerpt":"On February 27, 2023, Acadia Pharmaceuticals Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}